ABT Q3 2026 Earnings Analysis
Abbott reported Q3 2026 with 7% sales growth and 9% EPS growth, while announcing plans to spin off its $8.5B nutrition business by end of 2027 to focus on higher-growth healthcare markets.
Key Metrics
Wichtigste Erkenntnisse
- Abbott will spin off $8.5B nutrition business as independent company by end of 2027
- Q3 delivered 7% sales growth and 9% EPS growth with 140 bps margin expansion
- Strong momentum in EP (high-teens), cancer diagnostics (14%), and CGM (8%) growth
Anhören auf
Verfügbar in
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.
And I'm Jordan. We've got a genuinely big one today — Abbott Laboratories dropped some major news alongside their Q3 numbers.
We'll get to that in a second, but first — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
With that out of the way, Alex, let's start with the headline because it's not every day a 138-year-old company announces it's splitting itself in two.
Right — Abbott announced it's spinning off its entire nutrition business into a standalone, publicly traded company by the end of 2027. We're talking about Similac, PediaSure, Ensure, Glucerna, Pedialyte — the whole $8.5 billion nutrition empire, 16,000 employees, 14 manufacturing sites. CEO Robert Ford said this would actually be the largest pure-play healthy nutrition company in the world, and they expect it to qualify for S&P 500 inclusion on its own.
And the CEO pick is interesting too — Daniel Salvadori, who's run their Established Pharma and Nutrition division, is taking the reins of the new company. Ford called his team "battle-tested," which, if you've followed Abbott's infant formula saga the last few years — recalls, litigation, supply shortages — that's not an exaggeration.
The strategic logic here is basically: nutrition used to be a healthcare-professional-driven category, now it's a consumer wellness category, and those two worlds need different playbooks, different investment cycles, different marketing muscle. Ford's view is both companies do better focused and independent rather than living under one roof.
And for shareholders, it's structured as a tax-free spin — you'll own shares of both companies when it's done. Abbott's also planning to have the new nutrition company raise some debt, with proceeds flowing back to Abbott, and both companies will maintain investment-grade ratings.
What's the math on what's left behind? Because that's really the investor question here.
Right, this is the key number. CFO Phil Boudreau said stripping nutrition out of the current portfolio, Abbott's remaining business — MedTech, Diagnostics, Established Pharma — would see sales growth accelerate by 50 to 100 basis points, gross margin expand by over 200 basis points, and operating margin up roughly 100 basis points. So the pitch is: a leaner, faster-growing, higher-margin Abbott emerges on the other side.
Now let's talk actual Q3 results, because they were solid. Sales grew 7%, EPS grew 9% — both numbers accelerating from the first half of the year. Adjusted EPS came in at $1.42, right in line with guidance and consensus.
Breaking it down by segment — Diagnostics grew 6.5%, with Core Lab up 5.5% on strong demand across the U.S., Europe, Japan, and Latin America. But the real story there is Cancer Diagnostics, up 14%, largely thanks to the Exact Sciences integration — that's Cologuard. They also just launched their first blood-based colorectal cancer screening test in September, making Abbott the only company offering both stool-based and blood-based options.
Nutrition — even as it heads for the exit — actually had a good quarter. Sales up 5%, broad-based across all four categories. Pediatric nutrition was the standout at 9% growth, helped by those WIC contract wins that let Abbott reclaim market leadership.
Medical Devices grew 8%, led by electrophysiology and rhythm management, both posting double-digit growth. The Volt PFA catheter is gaining serious traction after its full U.S. launch in mid-August, and they got surprise early FDA approval for the TactiFlex Duo catheter in September.
But here's where it gets interesting in the Q&A — management actually trimmed full-year revenue guidance a bit, and Ford was refreshingly direct about why.
Two businesses, specifically. First, electrophysiology is facing a weird near-term headwind in left atrial appendage closure — basically, doctors are holding off on orders waiting for Abbott's new Amulet 360 device, which just got a CE Mark. Ford literally said orders slowed "almost immediately" after that approval news hit.
Which is a good problem to have, honestly — customers waiting for your next product.
Exactly, temporary pain for a reason. Second issue: diabetes care. CGM growth is expected to moderate to low-to-mid single digits for a few quarters, partly because the hoped-for CMS reimbursement expansion for non-insulin type 2 diabetics hasn't landed yet, and partly because of pricing pressure internationally as competition heats up in markets where Abbott holds 50-70% share.
Ford was pretty blunt that they're choosing to adjust pricing rather than lose share, which sounds like the right long-term call even if it dings growth briefly.
He also teased Libre Duo — the first dual glucose-ketone sensor — launching in December, plus a favorable U.S. payer formulary flip kicking in January 1. So the diabetes story isn't broken, just paused.
For 2027 guidance, Ford wouldn't commit to specifics until the January call, but he hinted at starting with a "similar" growth rate to this year before building up through the year — a more conservative approach than Abbott's historically taken on top-line guidance.
Worth noting too — he reiterated the pipeline is loaded: a mitral valve replacement program he's personally excited about, conduction system pacing, coronary IVL data coming at TCT, and an MRD cancer test readout at ESMO. R&D spend has nearly doubled since pre-COVID, crossing $3 billion this year.
So, bottom line for investors — accelerating growth this quarter, a historic corporate restructuring in motion, a couple of known, explainable soft spots in EP and diabetes, and a pipeline management insists is as strong as ever.
Everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
The next 12 to 14 months will be all about execution on this spin-off, plus watching whether Amulet 360 and TactiFlex Duo reignite that EP growth engine.
We'll be tracking it closely — this is a story with a lot more chapters to come.
Thanks for listening to Beta Finch — we'll catch you next time.